文献速递乳腺癌

远处无病生存可作为早期乳腺癌新辅助试验总生存替代终点

Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials.
PubMed 文献 · Lancet Oncol · 2025-01-01

BACKGROUND: The surrogacy value of distant disease-free survival for overall survival has not been validated in neoadjuvant randomised controlled trials (RCTs) for early breast cancer.…

要点

  • HR阴性/HER2阴性及HR阴性/HER2阳性亚型替代性强。
  • HR阳性/HER2阴性及HR阳性/HER2阳性亚型替代性弱。

核心结论

  • 在大多数情况下,DDFS是早期乳腺癌新辅助随机试验中预测最终OS的稳健替代终点。
  • 在激素受体阳性/HER2阴性和激素受体阳性/HER2阳性分子亚型中,DDFS的替代性似乎较弱。

研究设计与样本

  • 汇总分析纳入德国乳腺癌组(GBG)和德国妇科肿瘤乳腺研究组(AGO-B)开展的早期乳腺癌新辅助随机对照试验的个体患者数据。
  • 采用两阶段荟萃分析copula方法的试验水平替代性指标R2trial量化OS与DDFS治疗效应之间的关联。

临床怎么用

  • 在早期乳腺癌新辅助随机试验中,DDFS可作为OS的替代终点用于多数情境的疗效评估。
  • 对于激素受体阳性/HER2阴性和激素受体阳性/HER2阳性亚型,DDFS替代性弱,需谨慎解读以DDFS为主要终点的试验结果。

局限性

  • 这些较弱替代性发现需要在纳入更高危患者群体的更近期随机对照试验中进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The surrogacy value of distant disease-free survival for overall survival has not been validated in neoadjuvant randomised controlled trials (RCTs) for early breast cancer. Here, we assess the trial-level surrogacy value of distant disease-free survival for overall survival. METHODS: In this pooled analysis, we included individual patient data from RCTs of neoadjuvant therapy for early breast cancer conducted by the German Breast Group (GBG) and the German Gynecological Oncology Breast Study Group (AGO-B) with available data on distant disease-free survival and overall survival. We used the trial-level measure of surrogacy R2trial from two-stage meta-analytical copula methods to quantify the association between treatment effects on overall survival and distant disease-free survival, overall and in prespecified clinical and pathological subgroups. According to ReSEEM guidelines, R2trial values of 0·7 or higher represent strong correlations, values between 0·69 and 0·5 represent moderate correlations, and values of less than 0·5 represent weak correlations. FINDINGS: 11 RCTs, with a total of 15 neoadjuvant treatment comparisons and 12 247 patients, were included in the analysis. Overall, there was a strong association between copula model-based hazard ratios (HRs) for overall survival and copula model-based HRs for distant disease-free survival (R2trial=0·91 [95% CI 0·82-1·00]). No significant heterogeneity of results was observed across the majority of subgroups analysed (pheterogeneity>0·05 in all subgroups), with the exception of subgroups defined by tumour molecular features, such as tumour progesterone receptor status, HER2 status, and molecular subtypes. For molecular subtypes, the R2trial for the association between distant disease-free survival and overall survival was higher than 0·7, indicating strong surrogacy in hormone receptor-negative and HER2-negative tumours (R2trial=0·89 [95% CI 0·75-1·00]) and hormone receptor-negative and HER2-positive tumours (0·73 [0·36-1·00]), and below the 0·5 threshold for weak surrogacy in hormone receptor-positive and HER2-negative tumours (0·33 [0·00-0·83]) and hormone receptor-positive and HER2-positive tumours (0·11 [0·00-0·55]; pheterogeneity=0·021). INTERPRETATION: With adequate follow-up, distant disease-free survival is a robust surrogate endpoint for predicting final overall survival outcomes in neoadjuvant RCTs for early breast cancer in most contexts. However, the distant disease-free survival surrogacy appears to be weak for the hormone receptor-positive and HER2-negative and for the hormone receptor-positive and HER2-positive molecular subtypes. These latter findings warrant further investigation in more recent RCTs enrolling higher-risk patient populations. FUNDING: None.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Conforti F, Holtschmidt J, Nekljudova V, et al. Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials. Lancet Oncol. 2025. PMID: 41308675. doi:10.1016/S1470-2045(25)00546-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。